Switch theme
Sign up to access all valuation multiples
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
2001
897
LTM Revenue $685M
LTM EBITDA $174M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ANI Pharmaceuticals has a last 12-month revenue (LTM) of $685M and a last 12-month EBITDA of $174M.
In the most recent fiscal year, ANI Pharmaceuticals achieved revenue of $614M and an EBITDA of $63.1M.
ANI Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ANI Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $685M | XXX | $614M | XXX | XXX | XXX |
| Gross Profit | $425M | XXX | $364M | XXX | XXX | XXX |
| Gross Margin | 62% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $174M | XXX | $63.1M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $173M | XXX | $2.2M | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 0% | XXX | XXX | XXX |
| Net Profit | $114M | XXX | -$18.5M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | -3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $479M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ANI Pharmaceuticals's stock price is $59.
ANI Pharmaceuticals has current market cap of $1.3B, and EV of $1.8B.
See ANI Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.3B | XXX | XXX | XXX | XXX | $5.73 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ANI Pharmaceuticals has market cap of $1.3B and EV of $1.8B.
ANI Pharmaceuticals's trades at 2.9x EV/Revenue multiple, and 28.0x EV/EBITDA.
Equity research analysts estimate ANI Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ANI Pharmaceuticals has a P/E ratio of 11.1x.
See valuation multiples for ANI Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.1x | XXX | 28.0x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 795.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.1x | XXX | -68.7x | XXX | XXX | XXX |
| EV/FCF | 21.1x | XXX | 37.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialANI Pharmaceuticals's last 12 month revenue growth is 18%
ANI Pharmaceuticals's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.
ANI Pharmaceuticals's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ANI Pharmaceuticals's rule of X is 71% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ANI Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 37% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 71% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ANI Pharmaceuticals acquired XXX companies to date.
Last acquisition by ANI Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . ANI Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ANI Pharmaceuticals founded? | ANI Pharmaceuticals was founded in 2001. |
| Where is ANI Pharmaceuticals headquartered? | ANI Pharmaceuticals is headquartered in United States of America. |
| How many employees does ANI Pharmaceuticals have? | As of today, ANI Pharmaceuticals has 897 employees. |
| Who is the CEO of ANI Pharmaceuticals? | ANI Pharmaceuticals's CEO is Mr. Nikhil Lalwani. |
| Is ANI Pharmaceuticals publicy listed? | Yes, ANI Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of ANI Pharmaceuticals? | ANI Pharmaceuticals trades under ANIP ticker. |
| When did ANI Pharmaceuticals go public? | ANI Pharmaceuticals went public in 1999. |
| Who are competitors of ANI Pharmaceuticals? | Similar companies to ANI Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ANI Pharmaceuticals? | ANI Pharmaceuticals's current market cap is $1.3B |
| What is the current revenue of ANI Pharmaceuticals? | ANI Pharmaceuticals's last 12 months revenue is $685M. |
| What is the current revenue growth of ANI Pharmaceuticals? | ANI Pharmaceuticals revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of ANI Pharmaceuticals? | Current revenue multiple of ANI Pharmaceuticals is 2.6x. |
| Is ANI Pharmaceuticals profitable? | Yes, ANI Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ANI Pharmaceuticals? | ANI Pharmaceuticals's last 12 months EBITDA is $174M. |
| What is ANI Pharmaceuticals's EBITDA margin? | ANI Pharmaceuticals's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of ANI Pharmaceuticals? | Current EBITDA multiple of ANI Pharmaceuticals is 10.1x. |
| What is the current FCF of ANI Pharmaceuticals? | ANI Pharmaceuticals's last 12 months FCF is $83.5M. |
| What is ANI Pharmaceuticals's FCF margin? | ANI Pharmaceuticals's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of ANI Pharmaceuticals? | Current FCF multiple of ANI Pharmaceuticals is 21.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
